Cancer Immunology, Immunotherapy

, Volume 60, Issue 6, pp 869–882

Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity

  • Mónica Bernal
  • Angel Concha
  • Pablo Sáenz-López
  • Ana Isabel Rodríguez
  • Teresa Cabrera
  • Federico Garrido
  • Francisco Ruiz-Cabello
Original Article

Abstract

Purpose

To analyze the correlation of genomic instability with leukocyte infiltrate in gastrointestinal carcinomas (GIACs) and with tumor immunogenicity, e.g., HLA class I cell surface expression defects and galectin-3 and PDL-1 expression.

Experimental design

Lymphocyte and macrophage infiltrations were immunohistochemically studied in HLA class I negative GIACs with sporadic high-level microsatellite instability (MSI-H) or microsatellite stability (MSS).

Results

Tumors with MSI-H were associated with the following: dense infiltration (CD45, P < 0.001); cytotoxic CD8-positive lymphocytes (P < 0.001); and a complete absence of HLA class I cell surface expression, due to inactivating β2-microglobulin (β2-m) mutation in 50% of cases. In contrast, HLA class I negative tumors with MSS were significantly associated with fewer CD8-positive lymphocytes. There was no association between microsatellite instability and other molecular features of the tumor cells, including expression of galectin-3. Finally, macrophage infiltrate in the tumors was not correlated with microsatellite instability or HLA class I cell surface expression (CD64, P = 0.63; CD163, P = 0.51).

Conclusions

Microsatellite instability appears to be the most important factor determining the composition, density, and localization of leukocyte infiltrate, which is independent of other molecular features such expression of HLA class I cells, galectin-3, or programmed death ligand-1. Accordingly, the strong intratumoral CD8+ T infiltration of MSI-H tumors may be produced by elevated levels of specific inflammatory chemokines in the tumor microenvironment.

Keywords

Gastrointestinal adenocarcinomas (GIACs) Microsatellite instability (MSI) HLA class I Tumor leukocyte infiltrate 

Abbreviations

APM

Antigen processing machinery

CRC

Colorectal cancer

GIAC

Gastrointestinal adenocarcinoma

HLA

Human leukocyte antigen

LOH

Loss of heterozygosity

MHC

Major histocompatibility complex

MMR

Mismatch repair

MSI

Microsatellite instability

MSI-H

High microsatellite instability, MSS, microsatellite stability

References

  1. 1.
    Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRefGoogle Scholar
  2. 2.
    Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50PubMedCrossRefGoogle Scholar
  3. 3.
    Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203–208PubMedCrossRefGoogle Scholar
  4. 4.
    Robbins PF, Kawakami Y (1996) Human tumor antigens recognized by T cells. Curr Opin Immunol 8:628–636PubMedCrossRefGoogle Scholar
  5. 5.
    Boon T, Coulie PG, Van den Eynde BJ, Van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208PubMedCrossRefGoogle Scholar
  6. 6.
    Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439PubMedCrossRefGoogle Scholar
  7. 7.
    de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37PubMedCrossRefGoogle Scholar
  8. 8.
    Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396:643–649PubMedCrossRefGoogle Scholar
  9. 9.
    Perucho M (2003) Tumors with microsatellite instability: many mutations, targets and paradoxes. Oncogene 22:2223–2225PubMedCrossRefGoogle Scholar
  10. 10.
    Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macrì E, Fornasarig M, Boiocchi M (1999) High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154:1805–1813PubMedCrossRefGoogle Scholar
  11. 11.
    Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417–2422PubMedCrossRefGoogle Scholar
  12. 12.
    Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93:6–11PubMedCrossRefGoogle Scholar
  13. 13.
    Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 98:13255–13260PubMedCrossRefGoogle Scholar
  14. 14.
    Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13PubMedCrossRefGoogle Scholar
  15. 15.
    Peng W, Wang HY, Miyahara Y, Peng G, Wan RF (2008) Tumor-Associated Galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68:7228–7236PubMedCrossRefGoogle Scholar
  16. 16.
    Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034PubMedCrossRefGoogle Scholar
  17. 17.
    Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274PubMedCrossRefGoogle Scholar
  18. 18.
    Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215PubMedCrossRefGoogle Scholar
  19. 19.
    Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666PubMedCrossRefGoogle Scholar
  20. 20.
    Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRefGoogle Scholar
  21. 21.
    Allavena P, Sica A, Garlanda C, Mantovani A (2008) The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222:155–161PubMedCrossRefGoogle Scholar
  22. 22.
    Sobin L, Gospodarowiaz M, Wittekind CH (2009) TNM classification of malignant tumours UICC, 7th edn. Wiley, BlackwellGoogle Scholar
  23. 23.
    López Nevot MA, Cabrera T, de la Higuera B, Ruiz-Cabello F, Ga-rrido F (1986) Obtención y caracterización de anticuerpos monoclonales frente a leucemias humanas. Inmunología 5:51–59Google Scholar
  24. 24.
    Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306PubMedGoogle Scholar
  25. 25.
    Huelin C, Gonzalez M, Pedrinaci S, de la Higuera B, Piris MA, San Miguel J, Ruiz-Cabello F, Garrido F (1988) Distribution of the CD45R antigen in the maturation of lymphoid and myeloid seri-es.- The CD45R negative phenotype is a constant finding in T CD4 positive lympho-proliferative disor-ders. British J Haematol 69:173–179CrossRefGoogle Scholar
  26. 26.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMedGoogle Scholar
  27. 27.
    Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418–6424PubMedCrossRefGoogle Scholar
  28. 28.
    Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253PubMedCrossRefGoogle Scholar
  29. 29.
    Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61:211–219PubMedCrossRefGoogle Scholar
  30. 30.
    Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H (2007) HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 7:33PubMedCrossRefGoogle Scholar
  31. 31.
    Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95PubMedCrossRefGoogle Scholar
  32. 32.
    Marincola FM, Jaffee E, Hicklin D et al (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMedCrossRefGoogle Scholar
  33. 33.
    Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81PubMedCrossRefGoogle Scholar
  34. 34.
    D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S (1991) Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284–292PubMedCrossRefGoogle Scholar
  35. 35.
    Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108PubMedCrossRefGoogle Scholar
  36. 36.
    Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F et al (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529PubMedCrossRefGoogle Scholar
  37. 37.
    Paschen A, Méndez RM, Jiménez P, Sucker A, Ruiz-Cabello F, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759–767PubMedCrossRefGoogle Scholar
  38. 38.
    Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2:1427–1433PubMedGoogle Scholar
  39. 39.
    Ye Q, Shen Y, Wang X, Yang J, Miao F, Shen C, Zhang J (2010) Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens 75:30–39PubMedCrossRefGoogle Scholar
  40. 40.
    Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, Schwitalle Y, Kuchenbuch B et al (2007) Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 121:454–458PubMedCrossRefGoogle Scholar
  41. 41.
    Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 4:14PubMedGoogle Scholar
  42. 42.
    Kloor M, Michel S, von Knebel Doeberitz M (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127:1001–1010PubMedCrossRefGoogle Scholar
  43. 43.
    Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macrí E, Lanza G, Boiocchi M, Dolcetti R (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favourable prognosis. Am J Pathol 159:297–304PubMedCrossRefGoogle Scholar
  44. 44.
    Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004) Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 91:469–475PubMedCrossRefGoogle Scholar
  45. 45.
    Banerjea A, Ahmed S, Hands RE, Huang F, Han X, Shaw PM, Feakins R, Bustin SA, Dorudi S (2004) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 3:21PubMedCrossRefGoogle Scholar
  46. 46.
    Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 42:541–546PubMedCrossRefGoogle Scholar
  47. 47.
    Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F (2005) Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 54:858–866PubMedCrossRefGoogle Scholar
  48. 48.
    Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472–1479PubMedCrossRefGoogle Scholar
  49. 49.
    Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer 8:618–631PubMedCrossRefGoogle Scholar
  50. 50.
    Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51PubMedCrossRefGoogle Scholar
  51. 51.
    Nangia-Makker P, Balan V, Raz A (2008) Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron 1:43–51PubMedCrossRefGoogle Scholar
  52. 52.
    Lahm H, Andre S, Hoeflich A et al (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127:375–386PubMedCrossRefGoogle Scholar
  53. 53.
    Lotan R, Matsushita Y, Ohannesian D et al (1991) Lactose binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr Res 213:47–57PubMedCrossRefGoogle Scholar
  54. 54.
    Miyazaki J, Hokari R, Kato S et al (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312PubMedGoogle Scholar
  55. 55.
    Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E et al (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800PubMedGoogle Scholar
  56. 56.
    Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS (2010) PD-1 and PDL-1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. [Epub ahead of print] PubMed PMID: 20473887Google Scholar
  57. 57.
    Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C (2006) PDL-1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45:520–528PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Mónica Bernal
    • 1
  • Angel Concha
    • 2
  • Pablo Sáenz-López
    • 1
  • Ana Isabel Rodríguez
    • 1
  • Teresa Cabrera
    • 1
    • 3
  • Federico Garrido
    • 1
    • 3
  • Francisco Ruiz-Cabello
    • 1
    • 3
  1. 1.Servicio de Análisis Clínicos e InmunologíaHospital Universitario Virgen de las NievesGranadaSpain
  2. 2.Servicio de Anatomía PatológicaHospital Universitario Virgen de las NievesGranadaSpain
  3. 3.Departamento de Bioquímica, Biología Molecular III e Inmunología, Facultad de MedicinaGranadaSpain

Personalised recommendations